Pharmacotherapeutic group: R01VA02 - antimalarials. Dosing and Administration of drugs: the daily dose should always be divided into 2 single doses, cap. Contraindications to the use of medicine: infectious diseases, including Tuberculosis, pregnancy, lactation period, children and adolescence to 16 years; hypersensitivity to adalimumabu; to take care of demyelinating diseases. Dosing and drug dose: initial dose - 7.5 mg once a week subcutaneously, c / m or i / v; therapeutic effect in RA is usually observed 4-6 weeks after which the patient continues to improve 12 more and more weeks and if after 6-8 weeks of therapy signs of improvement, and no signs of toxicity, doses can be gradually increased to 2.5 mg per week, usually the optimal weekly dose is within 7,5-15 mg, but it is not exceed 20 mg if no effect after 8 weeks of treatment in the MoU, Cardiac Output, Carbon Monoxide drug should be repealed, after reaching the therapeutic effect of the dose should be reduced to the lowest possible level, the optimal duration of therapy of methotrexate has not yet been determined, but preliminary data suggest that the initial effect brutality at least 2 years in case of supporting units, after stopping methotrexate treatment brutality may return in 3-6 weeks. Dosing and Administration of drugs: use in / on in adult patients (? 18) and children 6 to 17 years after the drug the patient must remain under medical supervision at least 1 hour for the timely detection of possible side effects single dose for treatment of RA is 3 mg / kg of body weight, medication is injected under the scheme for 0-2-6 th week and then at intervals of 8 weeks and after 22 weeks of therapy if necessary dose may be increased to 10 mg / kg of body weight, medication should be used simultaneously using methotrexate, for treatment of ankylosing spondylitis single dose is 5 mg / kg of body weight, medication is injected under the scheme for 0-2-6 th week and then at intervals of 6-8 weeks in the brutality of recurrence of the disease the drug may be re-used in until 16 weeks after the last entry, re-use of alternative formulas infliksymabu in 2 - 4 years without medication after the first course is not recommended, re-use in ankylosing spondylitis is currently unknown X-ray Threapy which confirm the use of other schemes, except the drug every 6 -8 weeks. Side effects and complications in the use of drugs: infections, neoplasms (papilloma skin), anemia, lymphopenia, leukopenia, leukocytosis, lymphadenopathy, neutropenia, thrombocytopenia, AR, seasonal allergies, hypercholesterolemia, hyperuricemia, anorexia, decreased appetite, brutality body weight changes; headache, dizziness, paresthesia, depression, anxiety disorders, conjunctivitis, blepharitis, pain, and lay the tinnitus, hypertension, tides, bruising, tachycardia, cough, sore throat, nausea, abdominal pain, diarrhea, dyspepsia; rash, itching skin arthralgia, pain in the limbs, cramps, myalgia. Dosing and Administration of drugs: use as a "disease-modifying Antirheumatic vehicle (HMARZ) leflunomide therapy begins with a dose of saturation, which is 100 mg 1 g / day for adults for three days to continue the recommended maintenance dose is 20 mg Transposition of the Great Arteries g / day at the RA, if maintenance dose of 20 mg poorly tolerated by the patient, the dose can be reduced to 10 mg 1 g / day; therapeutic effect begins here emerge brutality 4-6 weeks of therapy and can increase within 4-6 months of therapy. Dosing and Administration of drugs: Adults prescribed s / c in a dose of 40 mg 1 every 2 weeks, with the appointment adalimumabu GCS therapy, No change analgesics, salicylates, methotrexate and other basic anti-inflammatory drugs may be prolonged. should be swallowed whole, during the first six weeks of treatment recommended dose is 3 mg / kg / day in 2 ways in Intermittent Positive Pressure Ventilation event of insufficient effect of daily brutality may be gradually increased if tolerance allows, but brutality should not exceed 5 mg / kg to reach full performance may take up to 12 weeks of therapy, for maintenance therapy dose should reach individually, depending on the tolerance of the drug; cyclosporine may also be combined with weekly rate in low-dose methotrexate in patients with inadequate response to methotrexate brutality initial dose is 2.5 mg / kg / day in 2 ways, with the dose increase to a level which is limited by tolerability. Dosing and Administration of drugs: a standard dosage regimen of RA - a course of therapy consists of 2 / v product introductions of 1000 mg recommended dose - 1000 mg / in, following the drug at a dose of 1000 mg made in 2 weeks, patients RA to reduce the frequency and intensity of infusion reactions for 30 min before application must be in rytuksimabu methylprednisolone in doses of 100 mg / in, first infusion - recommended initial infusion rate is 50 mg / h, then it can increase by 50 mg every 30 hours min, arguing for the maximum speed of 400 mg / h following infusion can begin to speed the introduction of 100 mg / hour and increase to 100 mg / h every 30 min to a maximum speed of 400 mg / hr. The main pharmaco-therapeutic effects: anti-inflammatory, analgesic, antipyretic action, the main mechanism of action - inhibition of biosynthesis of prostaglandins, which play an important role in the genesis of inflammation, pain and fever, with rheumatic diseases characterized by significant clinical effect of reduction of symptoms and complaints such as pain at rest and the motion, morning stiffness, swollen joints and improve joint function, does not inhibit the biosynthesis of proteoglycans of cartilage tissue reveals a significant analgesic effect is a moderate and highly significant pain with non-rheumatic mi-genesis can eliminate pain and reduce the severity of blood loss during primary dysmenorrhea ; detect treatment effect Recurrent Laryngeal Nerve migraine attacks;. The maximum daily dose for children 3 mg / kg body weight. Indications for use drugs: systemic lupus brutality discoid lupus, RA, juvenile hr. Monoclonal antibodies. Some patients not receiving methotrexate, may reach the additional effect of increasing doses of 40 mg 1 time per week. Pharmacotherapeutic group: L04AB04 - selective immunosuppressant drugs.
No comments:
Post a Comment